FDA Approves AbbVie's VENCLEXTA and Acalabrutinib Combination for First-Line CLL

The FDA has approved AbbVie's VENCLEXTA in combination with acalabrutinib for the first-line treatment of chronic lymphocytic leukemia (CLL). This approval provides a new treatment option for patients.